![Christy Oliger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christy Oliger
Directeur/Membre du Conseil chez
KARYOPHARM THERAPEUTICS INC.
Fortune : 95 883 $ au 31/07/2026
Profil
Christy J.
Oliger currently serves as Independent Director at Karyopharm Therapeutics, Inc. since 2020, Replimune Group, Inc. since 2021, Vera Therapeutics, Inc. since 2024, Bicara Therapeutics, Inc. since 2026, and Zenas BioPharma, Inc. since 2026.
Ms. Oliger is also a Director at Replimune, Inc. Former positions include Independent Director at Sierra Oncology, Inc. from 2021 to 2022, Independent Director at Reata Pharmaceuticals, Inc. from 2021 to 2023, Director at Rayzebio, Inc. from 2023 to 2024, Independent Non-Executive Director at LAVA Therapeutics NV from 2023 to 2025, Independent Director at Nuvalent, Inc. from 2025 to 2026, and Senior Vice President-Oncology Business Unit at Genentech, Inc. from 2017 to 2020.
Education includes undergraduate studies at the University of California, Santa Barbara.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2026 | 2 987 ( 0 % ) | 95 883 $ | 31/07/2026 | |
| 30/06/2026 | 0 ( -.--% ) | - $ | 31/07/2026 | |
| 21/05/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
Postes actifs de Christy Oliger
| Sociétés | Poste | Début |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Directeur/Membre du Conseil | 28/08/2020 |
| REPLIMUNE GROUP, INC. | Directeur/Membre du Conseil | 01/12/2021 |
| VERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 07/06/2024 |
| BICARA THERAPEUTICS INC. | Directeur/Membre du Conseil | 28/07/2026 |
Replimune, Inc.
 Replimune, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Directeur/Membre du Conseil | - |
Anciens postes connus de Christy Oliger
| Sociétés | Poste | Fin |
|---|---|---|
| NUVALENT, INC. | Directeur/Membre du Conseil | 15/07/2026 |
| LAVA THERAPEUTICS | Directeur/Membre du Conseil | 07/11/2025 |
| RAYZEBIO, INC. | Directeur/Membre du Conseil | 26/02/2024 |
| REATA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/06/2023 |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Christy Oliger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
LAVA Therapeutics NV
 LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Replimune, Inc.
Replimune, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune, Inc. is an American clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform, which is based on a herpes simplex virus type 1 backbone engineered to selectively destroy tumor cells, modify the tumor microenvironment, and induce a systemic anti-tumor immune response with enhanced T-cell activation. The company is located in the US. The company’s therapies are designed for direct injection into tumors to trigger local destruction and systemic immune activation, potentially overcoming resistance to existing immunotherapies. Its clinical pipeline includes candidates such as RP1 and RP2, being evaluated in advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma. Key clinical trials include the phase 3 IGNYTE-3 trial of RP1 with nivolumab in advanced melanoma, the ARTACUS trial for transplant patients with skin cancers, the REVEAL study in uveal melanoma, and the RP2-003 trial in liver cancer. Replimune retains commercial rights to its therapies and collaborates with partners for supply of checkpoint inhibitors used in combination regimens. The company also supports independent clinical investigations and funds medical education initiatives in oncology. | Commercial Services |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
